PYXIS ONCOLOGY INC
Pyxis Oncology (PYXS) is a clinical-stage biotechnology company focused on developing novel oncology therapies. As a small-cap firm (market capitalisation roughly $222.02M), the company’s value is closely tied to the progress of its development pipeline, clinical trial results and ability to secure additional funding or partnerships. Investors should expect significant volatility: clinical readouts can move the stock sharply in either direction and the company may require further capital raises that dilute existing shareholders. The stock may appeal to investors seeking exposure to early-stage biotech innovation, but it is higher risk than established pharmaceutical stocks. This summary is for general educational purposes only and not personalised investment advice. Past performance is not indicative of future returns, and investors should assess their risk tolerance, investment horizon and seek professional guidance before investing in speculative biotech equities.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Pyxis Oncology's stock, anticipating significant price growth potential.
Financial Health
Pyxis Oncology is performing well with strong profits and cash flow, but revenue growth needs attention.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring PYXS
FDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: October 12, 2025
Explore BasketPharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: October 5, 2025
Explore BasketPharma's Next Big Deal
This carefully curated group of stocks features promising biotech companies with valuable drug pipelines. These smaller firms could become the next targets for lucrative partnerships or acquisitions by pharmaceutical giants, similar to Glenmark's recent $2 billion deal with AbbVie.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage momentum
Progress in trials can materially affect valuation, offering potential milestones to watch — though outcomes are uncertain and may disappoint.
Small-cap dynamics
With a market capitalisation around $222M, the stock may see outsized moves and liquidity constraints; investors should be prepared for volatility.
Oncology focus
Concentration in cancer therapies means exposure to sector trends and regulatory scrutiny; this specialisation can create opportunities but also specific risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
